Evidence map›Paper›PMID 41126026›Full record

ArticleBMC microbiology2025

Research on the application of a high-throughput fully automated bacterial growth curve monitor for screening natural antibacterial compounds.

Shuangli Chen, Chengshuo Deng, Yixuan Liu, Xuanmei Huang, Xulong Chen, Guangyi Yang, Helu Liu

Abstract read
In one paragraph

Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Applying nephelometry for analyzing liquid yeast cultures.Biochemistry and biophysics reports · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shuangli Chen *Shenzhen Clinical College of Integrated Chinese and Western Medicine, Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518104, China.
Chengshuo Deng *Shenzhen Clinical College of Integrated Chinese and Western Medicine, Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518104, China.
Yixuan Liu *Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, Guangdong, 518104, China.
Xuanmei Huang *Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, Guangdong, 518104, China.
Xulong ChenThe Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510120, China.
Guangyi Yang *Shenzhen Clinical College of Integrated Chinese and Western Medicine, Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518104, China. 13971908298@163.com.
Helu Liu *Shenzhen Clinical College of Integrated Chinese and Western Medicine, Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518104, China. liuhelu@21cn.com.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province,China No. 2023A1515220253
6 · The paper itself

Abstract

backgroundThe emergence of multidrug-resistant bacteria poses a severe challenge to infection treatment, creating an urgent need for novel antimicrobial agents. Monomers derived from natural products exhibit multi-mechanism antibacterial properties with low resistance development potential. However, evaluation of these monomers is frequently hampered by color interference in traditional turbidimetric methods. This study developed a high-throughput fully automated bacterial growth curve monitor (HTFA-BGM) to provide a new tool for screening and assessing antimicrobial monomers.

methodsThe HTFA-BGM was designed and developed based on the principle of scattering nephelometry. Its performance in determining the minimum inhibitory concentration (MIC) was compared with the microdilution and the tube dilution methods. After establishing the instrument's MIC determination criterion, it was used to evaluate and screen the antibacterial effects of Traditional Chinese Medicine (TCM) monomers.

resultsThe HTFA-BGM could screen MICs of 40 monomers against one strain or one monomer against 40 strains simultaneously, unaffected by compound color. When a threshold of ≤ 10% for the ratio of sample turbidity change to bacterial suspension turbidity change was used as the MIC criterion, there was no significant difference between the HTFA-BGM method and the microdilution or tube dilution methods. The HTFA-BGM was used to evaluate 15 monomers (including polyphenolic, quinonoid, and other types of compounds), and the MIC of rhein against 90 strains of Methicillin-Resistant Staphylococcus aureus (MRSA) was 8–64 μg/mL. The synergistic rates of rhein combined with penicillin, cefoxitin, cefazolin or oxacillin against MRSA in vitro were 30% (27/90), 63% (57/90), 57% (51/90), and 58% (52/90), respectively, whereas the additive rates were 70% (63/90), 37% (33/90), 43% (39/90), and 42% (38/90), respectively. The MIC of oleanolic acid against 13 isolates of vancomycin-resistant Enterococcus (VRE) was 16–32 μg/mL. When combined with vancomycin, vancomycin MIC decreased from 256–1024 to 1 μg/mL.

conclusionThe HTFA-BGM enables automatic, real-time, and dynamic monitoring of bacterial growth curves. Compared with the microdilution method, which determines the MIC on the basis of endpoint turbidity, this instrument not only has improved efficiency but also yields more objective and accurate results. This method specifically resolves the interference caused by the intrinsic color of colored TCM monomers such as rhein during their determination tests. Therefore, it is better suited for evaluating and screening antibacterial TCM monomers. The HTFA-BGM demonstrates excellent practical applicability and warrants broad promotion and application.

Indexed as

Anti-Bacterial AgentsBacteriaBiological ProductsHigh-Throughput Screening AssaysMicrobial Sensitivity TestsNephelometry and TurbidimetryAnti-Bacterial AgentsBiological ProductsHigh-throughput fully automated bacterial growth curve monitorMinimum inhibitory concentrationMultidrug resistanceSynergistic effectsTraditional Chinese Medicine monomer

Identifiers

PMID41126026
PMCPMC12548153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.